About: New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
Source	Elsevier; Medline; PMC
abstract	Recently, a novel coronavirus (2019-nCoV), officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China. Despite drastic containment measures, the spread of this virus is ongoing. SARS-CoV-2 is the aetiological agent of coronavirus disease 2019 (COVID-19) characterised by pulmonary infection in humans. The efforts of international health authorities have since focused on rapid diagnosis and isolation of patients as well as the search for therapies able to counter the most severe effects of the disease. In the absence of a known efficient therapy and because of the situation of a public-health emergency, it made sense to investigate the possible effect of chloroquine/hydroxychloroquine against SARS-CoV-2 since this molecule was previously described as a potent inhibitor of most coronaviruses, including SARS-CoV-1. Preliminary trials of chloroquine repurposing in the treatment of COVID-19 in China have been encouraging, leading to several new trials. Here we discuss the possible mechanisms of chloroquine interference with the SARS-CoV-2 replication cycle.
has issue date	2020-03-12(xsd:dateTime)
bibo:doi	10.1016/j.ijantimicag.2020.105938
bibo:pmid	32171740
has license	no-cc
sha1sum (hex)	130a1a27637331d206d4a8af2827bf929c5a9694
schema:url	https://doi.org/10.1016/j.ijantimicag.2020.105938
resource representing a document's title	New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
has PubMed Central identifier	PMC7118659
has PubMed identifier	32171740
schema:publication	Int J Antimicrob Agents
resource representing a document's body	covid:130a1a27637331d206d4a8af2827bf929c5a9694#body_text
is schema:about of	named entity 'SARS-CoV-2' named entity 'SARS-CoV' named entity 'mechanisms of action' named entity 'chloroquine' named entity 'human immunodeficiency virus' named entity 'COVID-19' named entity 'chloroquine' named entity 'spike protein' named entity 'RNA' named entity 'iron metabolism' named entity 'envelope proteins' named entity 'chloroquine' named entity 'chloroquine' named entity 'sarcoidosis' named entity 'cathepsin' named entity 'SARS-CoV-2' named entity 'ACE2' named entity 'replication cycle' named entity 'control groups' named entity 'chloroquine' named entity 'post-translational modification' named entity 'gastrointestinal' named entity 'receptor' named entity 'amine' named entity 'Chloroquine' named entity 'antiviral' named entity 'proteases' named entity 'Cinchona trees' named entity 'SARS-CoV-2' named entity 'adverse effects' named entity 'biosynthesis' named entity 'protein' named entity 'China' named entity 'protein' named entity 'viral cycle' named entity 'cardiomyopathy' named entity 'glycosylation' named entity 'Vero cells' named entity 'intestine' named entity 'host tropism' named entity 'Dengue' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'virus' named entity 'broad-spectrum' named entity 'RNA viruses' named entity 'glycoprotein' named entity 'hepatitis A virus' named entity 'mRNA' named entity 'gp120' named entity 'antiviral' named entity 'fever' named entity 'upregulate' named entity 'sialic acids' named entity 'viral particles' named entity 'chloroquine' named entity 'SARS-CoV-2' named entity 'chloroquine' named entity 'virus' named entity 'protein' named entity 'antibodies' named entity 'immunomodulatory agent' named entity 'virus' named entity 'Chloroquine' named entity 'endolysosomal pathway' named entity 'virions' named entity 'anti-inflammatory response' named entity 'chloroquine' named entity 'T-cell' named entity 'endosome' named entity 'MAPK' named entity 'protease' named entity 'chloroquine' named entity 'quinine' named entity 'p38 MAPK' named entity 'Plasmodium falciparum malaria' named entity 'gene expression' named entity 'transmembrane' named entity 'SARS-CoV-1' named entity 'Chloroquine' named entity 'caspase-1' named entity 'subgenomic mRNA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software